Get insights. Better health.

Jacqueline Thongco-founder / CEO

Healthcare is not serving the patient...

OK, I’ll give it a try but I’ve already tried so many different meds!

I’m not sure what to recommend for your increased pain... maybe you can try this new drug?

Big data... big dealPower of secondary data lost if not used to change healthcare delivery

01

0 1

010

1

0

10

0 11

01

10 1

100

1 1

0

1101

01

0

1 01

01

1

0

10

01 0 0

1 1

01

0

1

0

01

001

0

10

01

1

0

01

1

0

0

1

0

0

100

01

1

01

0

1 1

01

10

How can patient data be useful?

Personal Discovery Engine

DISEASE TRACKER

PASSIVE MOBILE/DEVICE DATA

3RD PARTY DATA

PERSONALIZED FEEDBACK

CLINICAL EFFECTIVENESS

ITERATE

Ubiqi provides a structured experiment framework

BASELINE SAMPLE HYPOTHESES

We power “citizen science” through n=1 experiments

A B B A

A A B B

RANDOMIZATION OUTCOME AGGREGATION

PATIENT:Identify triggersUnderstand symptomsCompare therapiesReport side-effects

HEALTHCARE ORGANIZATIONS:Understand patient behaviorAnalyze patient responseCompare therapiesReview safety data

Apply same framework across multiple conditions

pain respiratory gastrointestinal

We create value for many healthcare organizations

PATIENT

PAYER

PHARMACY BENEFITS

MGMT

PHARMACY CHAINS PROVIDERS DISEASE

MGMT

PHARMA HEALTHCARE IT (EMR)

$1-5PER USER PER MONTH

Software-as-a-Service revenue model

$50-100KBASE SETUP

1X

GROWS WITH USER BASEONE-TIME FEE

Addressable market is 63M people in US alone

250MAMERICANS COVERED BY HEALTH INSURANCE

125MHAVE CHRONIC CONDITION

63MBENEFIT FROM SELF-MANAGING

OUR ADDRESSABLE MARKET

Ubiqi has a unique approachACTIONABLE INSIGHTS

PATIENT-DRIVEN PROTOCOLS

CONDITION TRACKING

PROVIDER-DRIVEN PROTOCOLS

UBIQI

RINGFUL HEALTH

STUDY CURE

GENOMERA

THECARROT

30+ years of experience in healthcare, technology, and design

Jacqueline Thong, CEOAnshuman Sharma, CTOWilliam Tang, Design Lead

ADVISORS ESTHER DYSONJAYANT PARTHASARATHY, PHDCHRIS ADAMS, MBA, PHDEGILIUS SPIERINGS, MD, PHDMATTHEW MAMET

We have strong resultsFrom initial migraine minimum viable product: 18K+ patients 20% active for more than 6 months Positive health outcomes!

Paying customer

Partnerships

In discussion

Partnerships

Go-to-market approach

MIGRAINEMVP

REPLICATE MODEL FORBACK PAIN

MINIMUM VIABLE PRODUCT - Prove utility to patients- Gather data- Evaluate pharma interest- Validate pharma revenue model

REFINEPRODUCT FOR

MIGRAINE

REFINE PLATFORM - Prove clinical validity - Gather data- Scale pharma model- Evaluate payer interest

SCALE PLATFORM - Prove utility beyond migraine- Gather data- Validate payer revenue model

Payers are our key target; first build credibility

2013 $600K

2014 $4M

2015 $16M

PHARMA PILOTS

SCALE PHARMA MODEL

PAYER PILOTS

SCALE PAYER MODEL

2016 $45M

2017 $75M REVENUE

Seeking guidance in partnership development and $700KKEY USE OF FUNDS FOR Q12013 - Q42013

3%3%

9%

10%

20%

55%

R&DBusiness developmentCOGSAdminB2B MarketingUser acquisition

We envision acquisition by a payer or disease management company

Disease management companies

Healthcare payers

That’s great! Let’s work together to make that even better.

I saw that when I do yoga AND take the new meds, my daily pain scores are 20% lower!

Help us create this alternative future!

Get insights. Better health.

Jacqueline Thongco-founder / CEOjacqueline@ubiqihealth.com+1 617 794 2089www.ubiqihealth.com

Financial projections

ROI to pharmaExample: Eli Lilly / Boehringer-Ingelheim’s Tradjenta

Revenues are $3.5B annually (2.3M pts)Adherence is 50% for oral anti-diabetic medicationsEstimated $1.75B revenue lost per year250K patients enroll in UbiqiAt $5 per patient per monthB-I PAYS UBIQI $1.25M (1 year)

10% of users get better results25K patients increase adherence to 75%B-I INCREASES REVENUES BY: +$47M (1 year)

ROI to payersExample: Aetna has 16 million subscribers

8% have asthma, costs them $2500/pt25% enroll in Ubiqi program: 320K subscribersAt $1 per member per month...AETNA PAYS UBIQI $3.8M (1 year)

25% of users get better results80K subscribers reduce ER visits, hospital visits, unnecessaryprescription meds, save $500 each/yrAETNA SAVES: $40M (1 year)

Intellectual PropertyItems we anticipate constitute defensible IP:i) process of taking structured / unstructured data and extractingfeature sets that are disease-specific and map to clinical evidence;

ii) learning engine which allows user to construct personalizedexperiments that they can run to create evidence;

iii) algorithm that makes suggestions on what pieces of anexperiment the user might want to choose to ensure success basedon base-line and crowd-sourced data;

iv) algorithm that aims to increase the information contained inunstructured patient-reported data to have stronger mappingbetween evidence and outcomes